An observational study in Personality Disorders, sponsored by De Viersprong. Active, not recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by De Viersprong · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Personality Disorders with a site in Netherlands — 4 open to participants now, 5 under way, none of them phase 3. Personality Disorders · Netherlands.
Among the 10 studies in Personality Disorders with a site in Netherlands, this one is one of 4 that started in 2024, is one of 2 observational ones, and was the 7th registered.
127 studies on the registry are indexed under Personality Disorders; 25 are open to participants now.
Browse Personality Disorders studies →4 of the 10 studies in Personality Disorders with a site in Netherlands are open now. Recruiting first, the newest first:
Tilburg University · Sites in Netherlands
Ages 16+
Arkin · Sites in Netherlands
Ages 18–65
Arkin · Sites in Netherlands
Ages 18+
Parnassia Groep · Sites in Netherlands
Ages 18+
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 19 Personality Disorders studies recruiting now, 14 (74%) set no upper age limit and 5 (26%) stop at 75 or younger; 5 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 4 started in 2024.
This study's planned enrollment of 27 is below the median of 125 across 40 observational studies indexed under Personality Disorders.
Median enrollment 87 across the 8 interventional studies, 65 across the 2 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 10 have an industry lead sponsor. The 8 most frequent:
De Viersprong is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
De Viersprong has 1 study filed under Personality Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Personality Disorders with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06726187Parnassia GroepDSM-5 Personality Disorders in Adults With Autism | 2027-01-28 |
| NCT07950800ArkinFrom There Towards Now; Intervention for Jewish and Indonesian Post-war Generations | 2027-08-01 |
| NCT06471010De ViersprongB-DIT Feasibility Study | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Personality Disorders with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to explore the feasibility, acceptability, and effectiveness of a new blended psychotherapeutic treatment program based on Dynamic Interpersonal Therapy (B-DIT) for adult clients with personality pathology. Blended interventions have the potential to improve treatment accessibility and cost-effectiveness for individuals with personality pathology and promote a sense of agency and ownership among clients regarding their treatment as compared to traditional Face-to-Face (FTF) approaches. This may improve treatment outcome and recovery.
The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp, integrates FTF therapy and online modules into a cohesive treatment program. The program spans three phases: an individual phase lasting approximately two months, followed by a four-month group phase, and concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases.
The primary study aims are (1) to monitor and evaluate the feasibility of B-DIT; which includes evaluating client satisfaction, treatment drop-out rates, user parameters related to online modules, and an interview-based qualitative analysis of therapists' and clients' experiences; and (2) to gather initial effectiveness data based on Routine Outcome Monitoring (ROM) measurements, complemented by a Single Case Experimental Design (SCED). The research questions are as follows:
This study aims to explore the feasibility, acceptability, and effectiveness of a new blended psychotherapeutic treatment program based on Dynamic Interpersonal Therapy (B-DIT) for adult clients with personality pathology. B-DIT integrates face-to-face (FTF) therapy and online modules into a cohesive treatment program, offering potential advantages in terms of treatment accessibility and cost-effectiveness for individuals with personality pathology. Additionally, blended interventions may have added value compared to traditional FTF approaches by fostering a greater sense of agency and ownership among clients regarding their treatment. While e-health and blended interventions have demonstrated promising treatment outcomes across various mental health areas, there is limited evidence for interventions targeting personality pathology.
B-DIT, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp, addresses this gap and provides a blended intervention for clients with mild to moderately severe personality pathology. The program spans three phases: an individual phase lasting approximately two months, followed by a four-month group phase, and concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases.
The primary study aims are (1) to monitor and evaluate the feasibility of B-DIT; which includes evaluating client satisfaction, treatment drop-out rates, user parameters related to online modules, and conducting a qualitative analysis of therapists' and clients' experiences; and (2) to gather initial effectiveness data based on Routine Outcome Monitoring (ROM) measurements, complemented by a Single Case Experimental Design (SCED). The SCED allows drawing conclusions about effectiveness based on a relatively small sample, while accommodating potential refinements to the intervention during the study period. The following research questions will be addressed:
Participants in the study will receive care as usual. In complement to regular Routine Outcome Monitoring assessments as integrated part of treatment, participants will be asked to complete an additional 26-item questionnaire repeatedly during their treatment and over a one year follow-up period in a Single Case Experimental Design with four phases:
Phase A - Baseline Waiting List (before start of treatment) - with a minimum of 3 weeks; Phase B - Intensive treatment phase (10 weeks of individual treatment followed by 30 weeks of group treatment) - 30 weeks; Phase C - Booster treatment phase - 16 weeks; Phase D - Follow-up phase after the end of treatment - 12 months.
The (impact of) expectations with regards to their treatment will be assessed at baseline and at end of treatment. Clients and clinicians will be questioned about their experiences in the treatment program (at the end of treatment) by means of semi-structured qualitative interviews.
Clients referred to De Viersprong are eligible for B-DIT when they exhibit mild to moderately severe impairments in personality functioning (including both cluster B, C, or a mixed presentation within unspecified personality disorder). Clients typically present with persistent problems in specific areas of their functioning, and typically have had previous, unsuccessful treatments. Adequate functioning in at least one domain of life (such as family, work, other societal roles) should be ensured, which allows for the generalization of treatment gains during and after the relatively short-term/ low intensity intervention.
All patients that are referred to B-DIT at de Viersprong are eligible for the study.
Inclusion criteria for treatment referral:
General exclusion criteria for treatment at the Viersprong:
Additional exclusion criteria for the B-DIT treatment:
There are no additional inclusion/exclusion criteria for participation in the study, other than those that apply to treatment.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Blended Dynamic Interpersonal Therapy (B-DIT)
The B-DIT intervention, developed collaboratively by Dutch mental health care institute De Viersprong and OnlinePsyHulp (http://www.onlinepsyhulp.be), integrates FTF therapy and online modules into a cohesive treatment program for clients with personality pathology. Both FTF and online treatment components are anchored in the Dynamic Interpersonal Therapy (DIT) framework (Lemma et al., 2011).The program spans three phases: an individual phase lasting approximately two months, followed by a five-month group phase, concluding with a four-month booster phase to reinforce positive changes. Face-to-face therapy sessions and online treatment modules are utilized alternately and complementarily throughout all treatment phases. Both verbal psychotherapy and art therapy are offered as treatment modalities in the face-to-face treatment sessions. The program is implemented by a multidisciplinary team.
Personality functioning- Severity Indices of Personality Functioning
Personality functioning- Severity Indices of Personality Functioning (SIPP-60): a 60-item self-report ROM questionnaire Administered as part of Routine Outcome Monitoring at start of intervention and subsequently every treatment evaluation (at 12, 20 and 30 weeks after start of the intervention); at the end of treatment; and at two follow-up timepoints after the end of treatment (6 and 12 months follow-up)
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Personality functioning- Level of Personality Functioning
Personality functioning - Level of Personality Functioning Brief-Form 2.0 (LBFS-BF-2.0): a 12-item self-report ROM questionnaire. Administered as part of Routine Outcome Monitoring at start of intervention and subsequently every treatment evaluation (at 12, 20 and 30 weeks after start of the intervention); at the end of treatment; and at two follow-up timepoints after the end of treatment (6 and 12 months follow-up).
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Symptom distress
Brief Symptom Inventory (BSI): a 53-item self-report ROM questionnaire. Administered as part of Routine Outcome Monitoring at start of intervention and subsequently every treatment evaluation (at 12, 20 and 30 weeks after start of the intervention); at the end of treatment; and at two follow-up timepoints after the end of treatment (6 and 12 months follow-up)
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Overall functioning
Outcome Rating Scale (ORS): a 4-item self-report questionnaire. Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. During: * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Usability of the online portal
System Usability Scale (SUS): a 10-item self-report questionnaire
Time frame: End of treatment (end of phase C)
Agency
General Self-Efficacy Scale (GSES): a 10 item self-report questionnaire Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Epistemic Trust
4 selected items of the Questionnaire Epistemic Trust (QET) Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Reflective Functioning
Reflective Functioning Questionnaire (RFQ): a 8 item self-report questionnaire. Outcome measures of the Single Case Experimental Design are assessed using a composite questionnaire that is delivered to participants repeatedly in varying frequencies depending on the phase of treatment and respective phase of the SCED. * Phase A: weekly during the baseline waiting period with a minimum of three weeks. * Phase B: bi-weekly during the first intervention phase of 10 weeks individual treatment and second intervention phase of 20 weeks group treatment * Phase C: monthly during the third intervention phase (booster phase) of 16 weeks * Phase D: two-monthly during the follow-up phase of 12 months
Time frame: From baseline, throughout the intervention, to 12 months after end of treatment
Treatment expectations
Credibility and Expectancy Questionnaire (CEQ)
Time frame: Baseline - after indication for treatment; End of treatment (end of phase C)
Experiences of clients and clinicians
Semi-structured interviews with clients and clinicians
Time frame: End of phase C (booster phase)
Plan to share: No
Started Jun 2024 (actual). Primary completion is estimated for Oct 2027, 40 months after the start.
Primary completion moved once since we started tracking on Sep 25, 2026: Jun 2026 → Oct 2027, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
De Viersprong